Real-world outcomes following ibrutinib dose reduction in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.

Autor:	Shadman M; Fred Hutchinson Cancer Center, Seattle, WA, USA., Salkar M; AbbVie, North Chicago, IL, USA., Srivastava B; AbbVie, North Chicago, IL, USA., Karve S; AbbVie, North Chicago, IL, USA., Emond B; Analysis Group, Inc., Montréal, Canada., Gogna P; Analysis Group, Inc., Montréal, Canada., Manceur AM; Analysis Group, Inc., Montréal, Canada., Lafeuille MH; Analysis Group, Inc., Montréal, Canada., Rava A; Genesis Research Group, Hoboken, NJ, USA., Sun H; Genesis Research Group, Hoboken, NJ, USA., Howarth A; Genesis Research Group, Hoboken, NJ, USA., Tomicki S; Genesis Research Group, Hoboken, NJ, USA., Agatep B; Inovalon, Bowie, MD, USA., Jones B; Inovalon, Bowie, MD, USA., Franceschini E; AbbVie, North Chicago, IL, USA., Saifan C; AbbVie, North Chicago, IL, USA., Bacchus S; AbbVie, North Chicago, IL, USA., Roeker L; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stephens DM; Division of Hematology, University of North Carolina, Chapel Hill, NC, USA.
Jazyk:	angličtina
Zdroj:	Leukemia & lymphoma [Leuk Lymphoma] 2024 Oct 01, pp. 1-10. Date of Electronic Publication: 2024 Oct 01.
DOI:	10.1080/10428194.2024.2402814
Abstrakt:	This study used real-world data from three separate United States (US) databases to evaluate dosing patterns and time to next treatment (TTNT) following the first-incident adverse event (AE) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with first-line ibrutinib with and without dose reduction (DR). Median TTNT or death in patients with and without a DR following an AE in each database was as follows: Optum Clinformatics Data Mart (CDM): 59.5 and 30.6 months; ConcertAI: 27.1 and 18.0 months; and Medicare Fee-for-Service (FFS): 49.8 and 22.0 months, respectively. Median TTNT or death in patients with cardiac AEs, with and without a DR, was: Optum CDM: 44.4 and 22.9 months; ConcertAI: 29.9 and 18.3 months; and Medicare FFS: 49.6 and 14.0 months, respectively. Ibrutinib DR was associated with fewer outpatient visits and lower CLL/SLL-related medical costs. These findings suggest that utilizing ibrutinib DR may effectively manage tolerability without compromising clinical efficacy.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu